Mechanism for treatment of gastric cancer: indirect comparison of trastuzumab and apatinib
DOI:
https://doi.org/10.61173/8y7bh256Keywords:
Trastuzumab, apatinib, targeted therapies, drug combination, gastric cancerAbstract
Gastric cancer is the fifth most prevalent type of cancer globally. It is the third leading cause of cancer-related mortality worldwide. Gastroscopy serves as a dependable foundation for the medical professional’s diagnostic process. And a biopsy is more accurate. A medical professional utilizes CT, endoscopic ultrasound, PET, and laparoscopy to ascertain the stage of gastric carcinoma. As a disease with macromolecular and phenotypic heterogeneity, the main treatment for gastric cancer in its early stage is endoscopic resection. Advanced gastric cancer is commonly managed through sequential regimens of chemotherapy, initiated with a first-line treatment cocktail comprising platinum and fluorouracil. Targeted therapies approved for the treatment of gastric cancer include trastuzumab (first-line human epidermal growth factor receptor type 2 (HER2) positive patients), Apatinib (oral small molecule vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor), Lamuzumab (anti-angiogenesis second-line), and nivolumab or pembrolizumab (anti-PD-1 third-line). Therapeutic modalities approved for the management of gastric cancer encompass trastuzumab (as a first-line agent for patients with human epidermal growth factor receptor type 2 (HER2)-positive status), Apatinib (an oral small-molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), Lamuzumab (an anti-angiogenic agent for second-line therapy), and nivolumab or pembrolizumab (as third-line treatments targeting programmed cell death protein 1 (PD-1)). This article reviews the mechanism of action, clinical application and safety of apatinib and trastuzumab. Complexity, diversity of cancer and effect, safety of using drugs make the combination of drugs in trend.
References
Lordick, Gastric cancer, Lancet 396(10251) (2020) 635-648. gastric cancer, Gastric Cancer 24(3) (2021) 642-654. [2] A.P. Thrift, T.N. Wenker, H.B. El-Serag, Global burden of [17] M.S. Park, V. Ravi, D.M. Araujo, Inhibiting the gastric cancer: epidemiological trends, risk factors, screening VEGF-VEGFR pathway in angiosarcoma, epithelioid
and prevention, Nat Rev Clin Oncol 20(5) (2023) 338-349. hemangioendothelioma, and hemangiopericytoma/solitary [3] H. Kim, Y. Hwang, H. Sung, J. Jang, C. Ahn, S.G. Kim, fibrous tumor, Curr Opin Oncol 22(4) (2010) 351-355. K.Y. Yoo, S.K. Park, Effectiveness of gastric cancer screening [18] M. Zajkowska, E. Lubowicka, P. Malinowski, M. on gastric cancer incidence and mortality in a community-based Szmitkowski, S. Lawicki, Plasma levels of VEGF-A, VEGF B,
prospective cohort, Cancer Res Treat 50(2) (2018) 582-589. and VEGFR-1 and applicability of these parameters as tumor [4] Z. Song, Y. Wu, J. Yang, D. Yang, X. Fang, Progress in the markers in diagnosis of breast cancer, Acta Biochim Pol 65(4)
treatment of advanced gastric cancer, Tumour Biol 39(7) (2017) (2018) 621-628. 1010428317714626. [19] Y. Zhao, S. Guo, J. Deng, J. Shen, F. Du, X. Wu, Y. Chen, M. [5] D.T. Debela, S.G. Muzazu, K.D. Heraro, M.T. Ndalama, B.W. Li, M. Chen, X. Li, W. Li, L. Gu, Y. Sun, Q. Wen, J. Li, Z. Xiao, Mesele, D.C. Haile, S.K. Kitui, T. Manyazewal, New approaches VEGF/VEGFR-targeted therapy and immunotherapy in nonand procedures for cancer treatment: Current perspectives, small cell lung cancer: targeting the tumor microenvironment,
SAGE Open Med 9 (2021) 20503121211034366. Int J Biol Sci 18(9) (2022) 3845-3858. [6] Y.T. Lee, Y.J. Tan, C.E. Oon, Molecular targeted therapy: [20] N. Ferrara, R.S. Kerbel, Angiogenesis as a therapeutic
Treating cancer with specificity, Eur J Pharmacol 834 (2018) target, Nature 438(7070) (2005) 967-974. 188-196. [21] C.C. Santini, J. Longden, E.M. Schoof, C.D. Simpson, G.R. [7] W. Eiermann, G. International Herceptin Study, Trastuzumab Jeschke, P. Creixell, J. Kim, X. Wu, B.E. Turk, N. Rosen, P.I. combined with chemotherapy for the treatment of HER2-positive Poulikakos, R. Linding, Global view of the RAF-MEK-ERK metastatic breast cancer: pivotal trial data, Ann Oncol 12 Suppl module and its immediate downstream effectors, Sci Rep 9(1) 1 (2001) S57-62. (2019) 10865. [8] G. Li, H. Lin, R. Tian, P. Zhao, Y. Huang, X. Pang, L. Zhao, [22] N.L. Spector, Y. Yarden, B. Smith, L. Lyass, P. Trusk, K. B. Cao, VEGFR-2 inhibitor apatinib hinders endothelial cells Pry, J.E. Hill, W. Xia, R. Seger, S.S. Bacus, Activation of AMP- progression triggered by irradiated gastric cancer cells-derived activated protein kinase by human EGF receptor 2/EGF receptor
exosomes, J Cancer 9(21) (2018) 4049-4057. tyrosine kinase inhibitor protects cardiac cells, Proc Natl Acad [9] A.H. Boekhout, J.H. Beijnen, J.H. Schellens, Trastuzumab, Sci U S A 104(25) (2007) 10607-10612.
Oncologist 16(6) (2011) 800-810. [23] K. El-Sahwi, S. Bellone, E. Cocco, M. Cargnelutti, [10] N. Boku, HER2-positive gastric cancer, Gastric Cancer F. Casagrande, M. Bellone, M. Abu-Khalaf, N. Buza, F.A. Dean&Francis ISSN 2959-409X Tavassoli, P. Hui, D.A. Silasi, M. Azodi, P.E. Schwartz, T.J. [25] J. Huang, X. Chen, J. Guo, L. Song, Y. Mu, H. Zhao, C. Rutherford, S. Pecorelli, A.D. Santin, In vitro activity of Du, Apatinib combined with trastuzumab and albumin-bound pertuzumab in combination with trastuzumab in uterine serous paclitaxel for treatment of HER2+ breast cancer with brain
papillary adenocarcinoma, Br J Cancer 102(1) (2010) 134-143. metastases resistant to anti-HER2 TKIs: A case report, Oncol [24] A. Aboudaram, P. Loap, D. Loirat, S.B. Dhia, K. Cao, A. Lett 25(2) (2023) 56. Fourquet, Y. Kirova, Pertuzumab and trastuzumab combination [26] J. Yue, Z. Long, Meta-analysis of the efficacy and safety with concomitant locoregional radiotherapy for the treatment of trastuzumab combined with apatinib in the treatment of
of breast cancers with HER2 receptor overexpression, Cancers advanced gastric cancer, Altern Ther Health Med 30(6) (2024) (Basel) 13(19) (2021) 4790. 70-75.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
